Monoclonal antibody therapy in COVID-19

Area of Science:

• Immunology
• Virology
• Pathology

Background:

• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection causes COVID-19, characterized by inflammation, thrombosis, and organ damage.
• SARS-CoV-2 activates macrophages, releasing pro-inflammatory cytokines like IL-1, IL-6, and TNF, leading to endothelial damage and thrombus formation.
• The binding of SARS-CoV-2 to Toll-Like Receptors triggers IL-1β production, potentially causing a 'cytokine storm' and severe clinical consequences.

Discussion:

• Blockade of IL-1 with anti-inflammatory cytokines is a potential therapeutic strategy for COVID-19.
• Monoclonal antibodies (mABs) are laboratory-produced antibodies targeting the SARS-CoV-2 spike protein, used to neutralize the virus.
• mABs are primarily for high-risk, non-hospitalized patients, with combination therapy showing better results.

Key Insights:

• mABs bind to specific epitopes on the SARS-CoV-2 spike protein (S1 and S2 subunits), inhibiting viral entry into host cells.
• Therapeutic targets for mABs include individuals at high risk, such as the elderly and those with chronic conditions like diabetes, hypertension, and cardiovascular disease.
• While promising, mAB therapy for COVID-19 has potential side effects including allergic reactions, thrombotic events, and gastrointestinal or systemic symptoms.

Outlook:

• Further research is crucial to definitively establish the neutralizing efficacy of mABs against SARS-CoV-2.
• Mitigating or eliminating the adverse side effects associated with mAB therapy is a key area for future investigation.
• The development of COVID-19 therapies, including vaccines and mABs, has been accelerated by the pandemic.